Table 2.
Treatment details for microprolactinomas treated with dopamine agonists and macroprolactinomas treated with adjuvant medical therapy following surgery. Remission and relapse rates are presented in the two groups.
| Microprolactinomas | Macroprolactinomas | P | |
|---|---|---|---|
| Bromocriptine dose (mg) |
24/38 2.5 (2.5–5.0) |
13/23 2.5 (2.5–5.0) |
0.596 0.853 |
| Cabergoline dose (mg) |
14/38 0.5 (0.5–0.69) |
10/23 0.5 (0.5–1.0) |
0.596 0.123 |
| Surgical remission | — | 23% (9/40) | |
| Duration of treatment (months) | 25.0 (15.0–87.0) | 25.5 (10.0–43.0) | 0.404 |
| Long-term remission | 68% (26/38) | 43% (10/23) | 0.122 |
| PRL at the last control | 23.1 (12.4–35.8) | 32.9 (12.0–70.0) | 0.279 |
| Withdrawal of therapy | 16/38 | 3/23 | 0.022 |
| Normal PRL after withdrawal | 15.8% (6/38) | 0% (0/3) | 0.073 |